You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,018,352


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,018,352
Title:Peptide compositions and therapeutic uses thereof
Abstract: Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH--CH(CH.sub.2--SO.sub.3H)COOH or Arg-Gly-NH--CH(CH.sub.2--SO.sub.3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting cellular adhesion to RGD binding sites or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.
Inventor(s): Mackel; Michael J. (Portland, OR), Park; John (Santa Ana, CA)
Assignee: Allegro Pharmaceuticals, Inc. (San Juan Capistrano, CA)
Application Number:12/943,900
Patent Claims:1. A compound comprising a peptide, wherein the peptide comprises Glycine-Arginine-Glycine-Cysteic(Acid)-Threonine-Proline.

2. A compound according to claim 1 wherein the peptide has the structural formula: ##STR00017##

3. A pharmaceutical preparation comprising a compound according to claim 1 in combination with a pharmaceutically acceptable carrier.

4. A method of treating a tumor comprising administering to a subject in need thereof a compound according to claim 1, wherein said compound is bound to an antitumor agent.

5. A method of treating a tumor comprising administering to a subject in need thereof a compound according to claim 1, wherein said compound is in multimeric form, and is additionally bound to an antitumor agent.

6. The method according to claim 5 wherein the antitumor agent is selected from the group consisting of: cancer chemotherapeutic agents, biological response modifiers, vascularization inhibitors, hormone receptor blockers, cryotherapeutic agents; agents that destroy or inhibit neoplasia or tumorigenesis; alkylating agents; agents which directly kill cancer cells by attacking their DNA; cyclophosphamide; isophosphamide; nitrosoureas, agents which kill cancer cells by inhibiting changes necessary for cellular DNA repair; carmustine (BCNU); lomustine (CCNU); antimetabolites; agents that block cancer cell growth by interfering with DNA synthesis; 6-mercaptopurine; 5-fluorouracil (5FU); antitumor antibiotics; compounds that act by binding or intercalating DNA and inhibiting RNA synthesis; doxorubicin; daunorubicin; epirubicin; idarubicin; mitomycin-C; bleomycin; Vinca alkaloids; vincristine; vinblastine; steroid hormones; hormone inhibitors; hormone receptor antagonists; agents which affect the growth of hormone-responsive cancers; tamoxifen; herceptin; aromatase inhibitors; aminoglutethamide; formestane; triazole inhibitors; letrozole; anastrazole; steroidal inhibitors; exemestane; anti-angiogenic proteins; gene therapy agents; agents that inhibit angiogenesis or vascularization of tumors; meth-1; meth-2; thalidomide; bevacizumab (Avastin); squalamine; endostatin; angiostatin; Angiozyme; AE-941 (Neovastat); CC-5013 (Revimid); medi-522 (Vitaxin); 2-methoxyestradiol (2ME2, Panzem); carboxyamidotriazole (CAI); combretastatin A4 prodrug (CA4P); SU6668; SU11248; BMS-275291; COL-3; EMD 121974; IMC-C11; IM862; TNP-470; celecoxib (Celebrex); rofecoxib (Vioxx); interferon alpha; interleukin-12 (IL-12); biological response modifiers; bacillus calmette-guerin (BCG); monoclonal antibodies; interleukin-2, granulocyte colony stimulating factor (GCSF); PGDF receptor antagonists; herceptin; asparaginase; busulphan; carboplatin; cisplatin; carmustine; chlorambucil; cytarabine; dacarbazine; etoposide; flucarbazine; gemcitabine; hydroxyurea; ifosphamide; irinotecan; lomustine; melphalan; mercaptopurine; methotrexate; thioguanine; thiotepa; tomudex; topotecan; treosulfan; mitoazitrone; oxaliplatin; procarbazine; streptocin; taxol and taxotere.

7. A method for treating a disorder selected from the group consisting of neovascularization, neovascular glaucoma, diabetic retinopathy, retinal degeneration, dry macular degeneration, wet macular degeneration and corneal neovascularization comprising administering to a subject in need thereof a compound according to claim 1.

8. A method of inhibiting growth of tumor cells which bear integrins comprising administering to a subject in need thereof a compound according to claim 1 in an amount effective to antagonize said integrins.

9. The method of claim 8 wherein the compound of claim 1 is radiolabelled.

10. A method of inhibiting metastasis comprising administering to a subject in need thereof a compound according to claim 1.

11. A method of decreasing vitreoretinal or vitreomacular traction comprising administering to a subject in need thereof a compound according to claim 1.

12. A method of promoting vitreolysis, liquefaction of vitreous humor, or vitroretinal detachment comprising administering to a subject in need thereof a compound according to claim 1.

13. The method according to any of claims 7-12 wherein the compound according to claim 1 is multimeric.

14. A peptide comprising Glycine-Arginine-Glycine-Cysteic(Acid)-Threonine-Proline.

15. A peptide according to claim 14 having the structural formula: ##STR00018##

16. A pharmaceutical preparation comprising a peptide according to claim 14 in combination with a pharmaceutically acceptable carrier.

17. A compound having the structural formula: ##STR00019## wherein X' is selected from H, C.sub.1-C.sub.6 alkyl, phenyl and --SO.sub.3H; Y is selected from OH and NH.sub.2; and Z is selected from H and methyl.

18. A method for treating a disorder selected from the group consisting of neovascularization, neovascular glaucoma, diabetic retinopathy, retinal degeneration, dry macular degeneration, wet macular degeneration and corneal neovascularization comprising administering to a subject in need thereof a compound according to claim 17.

19. A method of inhibiting growth of tumor cells which bear integrins comprising administering to a subject in need thereof a compound according to claim 17 in an amount effective to antagonize said integrins.

20. A method of inhibiting metastasis comprising administering to a subject in need thereof a compound according to claim 17.

21. A method of decreasing vitreoretinal or vitreomacular traction comprising administering to a subject in need thereof a compound according to claim 17.

22. A method of promoting vitreolysis, liquefaction of vitreous humor, or vitreoretinal detachment comprising administering to a subject in need thereof a compound according to claim 17.

23. A compound of the formula: ##STR00020##

24. A method of treating a tumor comprising administering to a subject in need thereof a compound according to claim 23.

Details for Patent 9,018,352

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 01/10/1978 ⤷  Try a Trial 2029-11-10
Merck Teknika Llc TICE BCG bcg live For Injection 102821 06/21/1989 ⤷  Try a Trial 2029-11-10
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2029-11-10
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.